No Data
China National Accord Medicines Corporation Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
China National Accord Medicines Corporation (000028): The business performance in the third quarter has improved compared to the previous quarter, bullish on the subsequent recovery.
In the first 9 months of 2024, the company's revenue/parent net income/non-parent net income were 56.466/1.066/1.024 billion yuan, -0.2%/-10.4%/-10.4% year-on-year, meeting the performance express expectations; 3.
Sinopharm is consistent: report for the third quarter of 2024
Sinopharm is consistent: quick performance report for the first three quarters of 2024
china national accord medicines corporation (01099.HK) earned 1.066 billion RMB in the first nine months, a decrease of 10.4%.
Sinopharm (01099.HK) announced the performance of its subsidiary China National Accord Medicines Corporation (000028.SZ) for the first nine months, achieving a total operating income of 56.466 billion RMB, a slight decrease of 0.2% year-on-year. The attributable net profit to shareholders was 1.066 billion yuan, a decrease of 10.4%, with an earnings per share of 1.91 yuan.
Sinopharm (01099): China National Accord Medicines Corporation (000028.SZ) recorded a net profit attributable to the parent company of approximately 1.066 billion yuan in the first three quarters, a year-on-year decrease of 10.43%.
Sinopharm (01099) announced the performance of China National Accord Medicines Corporation (000028.SZ) in the first three quarters of 2024...
No Data
No Data